Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 29, 2025, titled "Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis".
Press Release Aug 29 2025
Filed with NSE · · 4 pages · English
Summary by 6ix AI
The trial met its primary endpoint, showing a significant treatment difference in patients achieving a meaningful biochemical response compared to placebo. Zydus Therapeutics plans to submit a regulatory application for Saroglitazar in the U.S. in the first quarter of the following year. The press release emphasizes the potential of Saroglitazar as a new treatment option for patients who have not responded to standard therapies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis
- Press Release 20-08-2025 Newspaperadvertisement20082025
- Press Release Aug 13 2025
- Press Release Aug 12 2025
- Press Release Aug 11 2025
Later from Zydus Lifesciences
- Press Release Sep 02 2025
- Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA®) for the U.S. market
- Press Release Sep 04 2025
- Press Release Sep 05 2025
- Press Release Sep 15 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences